Sandy Macrae - Feb 25, 2022 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
President, CEO and Director, Director
Signature
Alexander D. Macrae, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Feb 25, 2022
Transactions value $
-$294,351
Form type
4
Date filed
3/1/2022, 04:16 PM
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability -$294K -49.9K -14.37% $5.90 297K Feb 25, 2022 Direct F1, F2
transaction SGMO Common Stock Award $0 +224K +75.38% $0.00 521K Feb 25, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMO Stock Option (Right to Buy) Award $0 +605K $0.00 605K Feb 25, 2022 Common Stock 605K $5.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
F2 Includes: (a) 10,633 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 32,756 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 56,261 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023 and (c) 30,173 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 92,254 shares subject to such RSU grant that will vest in two remaining annual installments of 46,120 shares and 46,134 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F3 Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4 One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.